Northwestern Mutual Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.78M Buy
9,613
+757
+9% +$335K ﹤0.01% 877
2026
Q1
$3.95M Buy
8,856
+556
+7% +$259K ﹤0.01% 881
2025
Q4
$3.76M Sell
8,300
-7
-0.1% -$3.02K ﹤0.01% 863
2025
Q3
$3.25M Sell
8,307
-3,225
-28% -$1.35M ﹤0.01% 865
2025
Q2
$5.13M Sell
11,532
-1,505
-12% -$694K ﹤0.01% 675
2025
Q1
$6.32M Buy
13,037
+490
+4% +$228K 0.01% 592
2024
Q4
$5.05M Buy
12,547
+150
+1% +$69.5K ﹤0.01% 620
2024
Q3
$5.77M Sell
12,397
-3,545
-22% -$1.7M 0.01% 582
2024
Q2
$7.47M Buy
15,942
+7,647
+92% +$3.32M 0.01% 490
2024
Q1
$3.47M Sell
8,295
-322
-4% -$136K ﹤0.01% 650
2023
Q4
$3.51M Buy
8,617
+510
+6% +$188K ﹤0.01% 623
2023
Q3
$2.82M Sell
8,107
-781
-9% -$273K ﹤0.01% 636
2023
Q2
$3.13M Sell
8,888
-774
-8% -$261K ﹤0.01% 601
2023
Q1
$3.04M Buy
9,662
+122
+1% +$36.6K ﹤0.01% 586
2022
Q4
$2.75M Buy
9,540
+416
+5% +$127K ﹤0.01% 592
2022
Q3
$2.64M Sell
9,124
-23
-0.3% -$6.62K ﹤0.01% 547
2022
Q2
$2.58M Sell
9,147
-433
-5% -$116K ﹤0.01% 563
2022
Q1
$2.5M Buy
9,580
+2,024
+27% +$480K ﹤0.01% 588
2021
Q4
$1.66M Buy
7,556
+1,995
+36% +$388K ﹤0.01% 660
2021
Q3
$1.01M Sell
5,561
-662
-11% -$129K ﹤0.01% 767
2021
Q2
$1.25M Sell
6,223
-4,001
-39% -$837K ﹤0.01% 690
2021
Q1
$2.2M Sell
10,224
-3,385
-25% -$744K ﹤0.01% 493
2020
Q4
$3.22M Buy
13,609
+2,444
+22% +$561K 0.01% 390
2020
Q3
$3.04M Buy
11,165
+8,223
+280% +$2.27M 0.01% 362
2020
Q2
$855K Buy
2,942
+773
+36% +$210K ﹤0.01% 572
2020
Q1
$516K Buy
2,169
+268
+14% +$61.5K ﹤0.01% 634
2019
Q4
$416K Sell
1,901
-328
-15% -$66.4K ﹤0.01% 728
2019
Q3
$378K Sell
2,229
-55
-2% -$9.73K ﹤0.01% 702
2019
Q2
$419K Buy
2,284
+122
+6% +$21.3K ﹤0.01% 681
2019
Q1
$398K Buy
2,162
+281
+15% +$51.9K ﹤0.01% 678
2018
Q4
$312K Sell
1,881
-60
-3% -$10.4K ﹤0.01% 680
2018
Q3
$374K Buy
1,941
+125
+7% +$22.3K ﹤0.01% 633
2018
Q2
$309K Buy
1,816
+338
+23% +$52.4K ﹤0.01% 654
2018
Q1
$241K Buy
1,478
+410
+38% +$67K ﹤0.01% 694
2017
Q4
$160K Buy
1,068
+49
+5% +$7.25K ﹤0.01% 789
2017
Q3
$155K Buy
1,019
+31
+3% +$4.67K ﹤0.01% 764
2017
Q2
$127K Buy
988
+132
+15% +$15.9K ﹤0.01% 811
2017
Q1
$93K Sell
856
-547
-39% -$48.2K ﹤0.01% 848
2016
Q4
$103K Buy
+1,403
New +$114K ﹤0.01% 817
2016
Q3
Sell
-1,351
Closed -$116K 1498
2016
Q2
$116K Sell
1,351
-166
-11% -$14.3K ﹤0.01% 686
2016
Q1
$120K Buy
1,517
+357
+31% +$32.3K ﹤0.01% 657
2015
Q4
$146K Buy
1,160
+906
+357% +$109K ﹤0.01% 567
2015
Q3
$26K Sell
254
-48
-16% -$6.17K ﹤0.01% 854
2015
Q2
$37K Buy
302
+53
+21% +$6.68K ﹤0.01% 737
2015
Q1
$29K Buy
249
+34
+16% +$4.07K ﹤0.01% 780
2014
Q4
$26K Buy
215
+15
+8% +$1.69K ﹤0.01% 820
2014
Q3
$22K Hold
200
﹤0.01% 805
2014
Q2
$19K Buy
200
+36
+22% +$2.52K ﹤0.01% 780
2014
Q1
$12K Sell
164
-471
-74% -$37.3K ﹤0.01% 845
2013
Q4
$47K Buy
635
+587
+1,223% +$40.9K ﹤0.01% 615
2013
Q3
$4K Buy
+48
New +$3.82K ﹤0.01% 1061

Other funds holding VRTX

Northwestern Mutual Wealth Management's VRTX Position: Q2 2026 in Review

Northwestern Mutual Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 8.5% in Q2 2026, buying an estimated $335K and bringing the position to 9,613 shares worth $4.78M. The position accounts for ﹤0.01% of the portfolio, ranked #877.

Northwestern Mutual Wealth Management first reported a position in VRTX in Q3 2013 and has held it in 51 quarters since. The position peaked at $7.47M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Northwestern Mutual Wealth Management held 9,613 shares of Vertex Pharmaceuticals worth $4.78M as of Q2 2026.
  • Northwestern Mutual Wealth Management bought 757 Vertex Pharmaceuticals shares in Q2 2026, an estimated $335K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #877 holding.
  • Northwestern Mutual Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Northwestern Mutual Wealth Management's Vertex Pharmaceuticals position peaked at $7.47M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.